Effects of Nintedanib on Dyspnea, Cough and Quality of Life in Patients with Progressive Fibrosing Interstitial Lung Diseases: Findings from the INBUILD Trial

被引：0
|
作者：
Swigris, J. J. [1 ]
Richeldi, L. [2 ]
Wijsenbeek, M. [3 ]
Kreuter, M. [4 ,5 ]
Nunes, H. [6 ]
Suda, T. [7 ]
James, A. [8 ]
Rohr, K. B. [8 ]
Quaresma, M. [8 ]
Flaherty, K. R. [9 ]
机构：
[1] Natl Jewish Hlth, Denver, CO USA
[2] Univ Cattolica Sacro Cuore, Fdn Policlin A Gemelli IRCCS, Rome, Italy
[3] Univ Med Ctr, Erasmus MC, Dept Resp Med, Rotterdam, Netherlands
[4] Heidelberg Univ, Thoraxklin, Ctr Interstitial & Rare Lung Dis, Pneumol & Resp Care Med, Heidelberg, Germany
[5] German Ctr Lung Res, Heidelberg, Germany
[6] Hop Avicenne, APHP, Dept Pulmonol, Bobigny, France
[7] Hamamatsu Univ Sch Med, Dept Internal Med, Hamamatsu, Shizuoka, Japan
[8] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[9] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2754
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effects of nintedanib on dyspnoe, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial
    Kreuter, M.
    Swigris, J. J.
    Richeldi, L.
    Wijsenbeek, M.
    Nunes, H.
    Suda, T.
    James, A.
    Rohr, K. B.
    Quaresma, M.
    Flaherty, K. R.
    [J]. PNEUMOLOGIE, 2021, 75 : S24 - S24
  • [2] Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the INBUILD trial
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Mueller, Heiko
    Coeck, Carl
    Rohr, Klaus B.
    Kolb, Martin
    Brown, Kevin K.
    [J]. RESPIROLOGY, 2023, 28 (05) : 465 - 474
  • [3] Nintedanib in patients with chronic fibrosing Interstitial lung diseases with progressive phenotype: the INBUILD trial
    Koschel, D.
    Flaherty, K. R.
    Wells, A. U.
    Cottin, V
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S.
    Stowasser, S.
    Coeck, C.
    Goeldner, R. G.
    Clerisme-Beaty, E.
    Schlenker-Herceg, R.
    Brown, K. K.
    [J]. PNEUMOLOGIE, 2020, 74 : S106 - S107
  • [4] Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial
    Flaherty, Kevin R.
    Wells, Athol U.
    Cottin, Vincent
    Devaraj, Anand
    Inoue, Yoshikazu
    Richeldi, Luca
    Walsh, Simon
    Stowasser, Susanne
    Coeck, Carl
    Goeldner, Rainer-Georg
    Clerisme-Beaty, Emmanuelle
    Schlenker-Herceg, Rozsa
    Brown, Kevin K.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [5] Characteristics of Patients with Progressive Fibrosing Interstitial Lung Diseases (ILDs) in the INBUILD Trial of Nintedanib
    Flaherty, K. R.
    Wells, A. U.
    Clerisme-Beaty, E.
    Cottin, V.
    Devaraj, A.
    Inoue, Y.
    Richeldi, L.
    Walsh, S.
    Goeldner, R.
    Schlenker-Herceg, R.
    Brown, K. K.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [6] The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
    Matteson, Eric
    Kelly, Clive
    Distler, Joerg
    Mann-Vold, Anna Maria Hoff
    Seibold, James
    Mittoo, Shikha
    Distler, Oliver
    Goeldner, Rainer-Georg
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Quaresma, Manuel
    Flaherty, Kevin
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [7] THE INBUILD TRIAL OF NINTEDANIB IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES: SUBGROUP OF ASIAN PATIENTS
    Inoue, Yoshikazu
    Wells, Athol U.
    Song, Jin Woo
    Xu, Zuojun
    Kitamura, Hideya
    Suda, Takafumi
    Okamoto, Masaki
    Schlenker-Herceg, Rozsa
    Kolb, Martin
    Brown, Kevin K.
    Quaresma, Manuel
    Kolb, Martin
    Brown, Kevin K.
    [J]. RESPIROLOGY, 2019, 24 : 87 - 88
  • [8] Effect of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analyses from the INBUILD Trial
    Kolb, M. R.
    Flaherty, K. R.
    Silva, R. S.
    Prasse, A.
    Patel, N. M.
    Vancheri, C.
    Quaresma, M.
    Goeldner, R.
    Stowasser, S.
    Schlenker-Herceg, R.
    Wells, A. U.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [9] Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial
    Cottin, Vincent
    Martinez, Fernando J.
    Jenkins, R. Gisli
    Belperio, John A.
    Kitamura, Hideya
    Molina-Molina, Maria
    Tschoepe, Inga
    Coeck, Carl
    Lievens, Dirk
    Costabel, Ulrich
    [J]. RESPIRATORY RESEARCH, 2022, 23 (01)
  • [10] The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial
    Inoue, Yoshikazu
    Kitamura, Hideya
    Okamoto, Masaki
    Ogura, Takashi
    Nishioka, Yasuhiko
    Kuwana, Masataka
    Taniguchi, Atsushi
    Ito, Tomohiro
    Rohr, Klaus B.
    Suda, Takafumi
    [J]. RESPIRATORY INVESTIGATION, 2024, 62 (04) : 589 - 596
12345